Ceribell, Inc. ((CBLL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The Ceribell Delirium Data Collection Study aims to enhance the understanding and assessment of delirium subtypes by collecting clinical and rapid response EEG (rrEEG) data. This observational study, officially titled the ‘Ceribell Delirium Data Collection Study,’ is significant for its potential to develop software algorithms that could improve delirium diagnosis and treatment in clinical settings.
The study tests the use of an Electroencephalogram (EEG) device, which is intended to monitor and assess delirium in ICU patients. This device aims to provide valuable data that can aid in the development of future diagnostic tools.
Designed as a prospective, case-control observational study, the research does not involve random allocation or masking. Its primary purpose is to gather data over a six-day period to support the development of new clinical assessment tools.
The study began on June 29, 2021, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing progress and data collection.
This study update could positively impact Ceribell, Inc.’s stock performance by showcasing innovation and potential advancements in healthcare technology. It may also influence investor sentiment by highlighting Ceribell’s commitment to addressing critical healthcare challenges. Competitors in the medical device industry may need to monitor these developments closely.
The Ceribell Delirium Data Collection Study is currently recruiting, with further details available on the ClinicalTrials portal.